Celtrix' SomatoKine Fast Delivery Of IGF-1

16 June 1996

- Celtrix' SomatoKine (IGF-BP3) can deliver insulin-like growth factor-1 at much higher doses than previously possible, according to the results of an initial Phase I study. SomatoKine combines IGF with its major binding protein, BP3. Most naturally-occurring IGF-1 circulates in the body in this complexed form. The firm intends to study SomatoKine's effects as a hormone replacement in critically-ill patients, such as those undergoing major surgery, or with organ damage/failure and trauma, in a Phase II study later this fiscal year.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight